These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38279391)

  • 21. [Effects of glucocorticoids on the expression of GTIR and apoptosis of the CD4(+)CD25(+)CD127(dim/-) T cells in patients with systemic lupus erythematosus].
    Pan Y; Li XP; Sun JF; Wang L; Chen Z; Li XM; Tao JH; Qian L; Zhang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):215-20. PubMed ID: 22516990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent glucocorticoid resistance in systemic lupus erythematosus patients during clinical remission.
    Melo AK; Melo MR; Saramago AB; Demartino G; Souza BD; Longui CA
    Genet Mol Res; 2013 Jun; 12(2):2010-9. PubMed ID: 23479142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
    Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
    Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study.
    Abe K; Ishikawa Y; Kita Y; Yajima N; Inoue E; Sada KE; Miyawaki Y; Yoshimi R; Shimojima Y; Ohno S; Kajiyama H; Ichinose K; Sato S; Fujiwara M
    Arthritis Res Ther; 2022 Jul; 24(1):179. PubMed ID: 35902976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
    Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies.
    Siddiqi KZ; Wilhelm TR; Ulff-Møller CJ; Jacobsen S
    Transl Res; 2021 Dec; 238():63-75. PubMed ID: 34343626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial.
    Chantzichristos D; Svensson PA; Garner T; Glad CA; Walker BR; Bergthorsdottir R; Ragnarsson O; Trimpou P; Stimson RH; Borresen SW; Feldt-Rasmussen U; Jansson PA; Skrtic S; Stevens A; Johannsson G
    Elife; 2021 Apr; 10():. PubMed ID: 33821793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus.
    Jones SA; Toh AE; Odobasic D; Oudin MA; Cheng Q; Lee JP; White SJ; Russ BE; Infantino S; Light A; Tarlinton DM; Harris J; Morand EF
    Ann Rheum Dis; 2016 Apr; 75(4):739-47. PubMed ID: 26612340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case report for recurrent and new-onset SLE patients treated by high-dose glucocorticoid therapy: Characteristics of peripheral TCR beta chain CDR3 repertoires.
    Yu J; Shi B; Ma L; Liu C; Sun S; Ma R; Qiu Y; Yao X
    Medicine (Baltimore); 2017 Dec; 96(49):e9022. PubMed ID: 29245286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysfunction of TRIM21 in interferon signature of systemic lupus erythematosus.
    Kamiyama R; Yoshimi R; Takeno M; Iribe Y; Tsukahara T; Kishimoto D; Kunishita Y; Sugiyama Y; Tsuchida N; Nakano H; Minegishi K; Tamura M; Asami Y; Kirino Y; Ishigatsubo Y; Ozato K; Nakajima H
    Mod Rheumatol; 2018 Nov; 28(6):993-1003. PubMed ID: 29385873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
    Rodziewicz M; Dyball S; Lunt M; McDonald S; Sutton E; Parker B; Bruce IN;
    Lancet Rheumatol; 2023 May; 5(5):e284-e292. PubMed ID: 38251591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.
    Tarr T; Papp G; Nagy N; Cserép E; Zeher M
    Clin Rheumatol; 2017 Feb; 36(2):327-333. PubMed ID: 27889859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature.
    Hammond ER; Tummala R; Berglind A; Syed F; Wang X; Desta B; Nab H
    BMJ Open; 2020 Sep; 10(9):e036563. PubMed ID: 32873668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.
    Chiche L; Jourde-Chiche N; Whalen E; Presnell S; Gersuk V; Dang K; Anguiano E; Quinn C; Burtey S; Berland Y; Kaplanski G; Harle JR; Pascual V; Chaussabel D
    Arthritis Rheumatol; 2014 Jun; 66(6):1583-95. PubMed ID: 24644022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.
    Bennett L; Palucka AK; Arce E; Cantrell V; Borvak J; Banchereau J; Pascual V
    J Exp Med; 2003 Mar; 197(6):711-23. PubMed ID: 12642603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of potential biomarkers for systemic lupus erythematosus by integrated analysis of gene expression and methylation data.
    Zhang W; Liang G; Zhou H; Zeng X; Zhang Z; Xu X; Lai K
    Clin Rheumatol; 2023 May; 42(5):1423-1433. PubMed ID: 36595110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.